Log in
Enquire now
‌

US Patent 9970009 MicroRNA compounds and methods for modulating miR-21 activity

Patent 9970009 was granted and assigned to Regulus Therapeutics on May, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Regulus Therapeutics
Regulus Therapeutics
0
Current Assignee
Regulus Therapeutics
Regulus Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
99700090
Patent Inventor Names
Balkrishen Bhat0
Eric Marcusson0
Date of Patent
May 15, 2018
0
Patent Application Number
154415900
Date Filed
February 24, 2017
0
Patent Citations Received
‌
US Patent 11965162 MicroRNA and inhibitors thereof and methods of treatment
0
Patent Primary Examiner
‌
Ekaterina Poliakova-Georgantas
0
Patent abstract

Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9970009 MicroRNA compounds and methods for modulating miR-21 activity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.